Evidence map›Paper›PMID 41390158›Full record

ArticleThe British journal of ophthalmology2026

Impact of artificial intelligence on the availability, accessibility, acceptability and quality of ophthalmic disease screening services: a scoping review.

Senlin Lin, Juzhao Zhang, Catherine Jan, Liping Li, Yajun Peng, Dan Qian, Yao Yin, Mengjia Zhang, Jianxiu Feng, Mingguang He and 1 more

Abstract readScoping Review
In one paragraph

Article in The British journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Senlin Lin *Shanghai Eye Disease Prevention and Treatment Center/Shanghai Eye Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID http://orcid.org/0000-0002-0166-1308
Juzhao Zhang *Shanghai Eye Disease Prevention and Treatment Center/Shanghai Eye Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID http://orcid.org/0000-0002-8420-8276
Catherine Jan *Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia.
Liping Li *Shanghai Hongkou Center for Disease Control and Prevention, Shanghai, China.
Yajun PengShanghai Eye Disease Prevention and Treatment Center/Shanghai Eye Hospital, School of Medicine, Tongji University, Shanghai, China.
Dan QianEye and Dental Diseases Prevention and Treatment Center of Pudong New Area, Shanghai, China.
Yao YinDepartment of Ophthalmology, Fengcheng Hospital, Shanghai, China.
Mengjia ZhangKongjiang Hospital of Yangpu District, Shanghai, China.
Jianxiu FengKongjiang Hospital of Yangpu District, Shanghai, China.
Mingguang HeCentre for Eye and Vision Research, School of Optometry, The Hong Kong Polytechnic University, Hong Kong, Hong Kong zouhaidong@sjtu.edu.cn mingguang.he@unimelb.edu.au.
Haidong ZouShanghai Eye Disease Prevention and Treatment Center/Shanghai Eye Hospital, School of Medicine, Tongji University, Shanghai, China zouhaidong@sjtu.edu.cn mingguang.he@unimelb.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This scoping review examines the existing literature on the application of artificial intelligence (AI) in screening for eye diseases, with a focus on evaluating whether AI-assisted diagnostic technologies enhance the availability, accessibility, acceptability and quality of screening services. 42 original studies were selected for in-depth analysis, including those employing health economic evaluations. Methodological quality was assessed using the Mixed Methods Appraisal Tool, with the majority of studies demonstrating high quality-24 scored 5/5, 15 scored 4/5 and the rest scored 3/5. Among the included studies, 34 compared manual screening with either AI-assisted or fully AI-driven approaches. Availability was the most frequently studied aspect (28 studies), followed by acceptability (12 studies), whereas accessibility and service quality were less commonly addressed. Overall, AI shows significant potential to improve the cost-effectiveness of eye care services and enhance patient access, particularly in remote or underserved regions. It was also well-accepted by patients, with high satisfaction and improved referral compliance. The findings suggest that AI holds promise for advancing eye disease screening, although large-scale, long-term trials are needed to effectively integrate AI into the reconstruction of screening processes and the reshaping of eye health service systems.

Indexed as

Artificial IntelligenceEye DiseasesHealth Services AccessibilityMass ScreeningOphthalmologyPatient Acceptance of Health CareQuality of Health CareHumanspublic healthtelemedicine

Identifiers

PMID41390158
PMCPMC13217127

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.